A patient with a history of anxiety and mood disorder is experiencing increased cortisol levels, mild hyponatremia, cognitive decline, and persistent insomnia, potentially related to her current medication regimen that includes sertraline. Which nursing intervention is most appropriate to address her insomnia and cognitive issues while considering her medication side effects?

B) Suggest cognitive-behavioral therapy for insomnia (CBT-I) to improve sleep quality.

A) Recommend a gradual taper of sertraline to reduce hyponatremia risk.

B) Suggest cognitive-behavioral therapy for insomnia (CBT-I) to improve sleep quality.

C) Initiate melatonin supplements to promote sleep without affecting current medications.

D) Encourage increased daytime physical activity to reduce cortisol levels.

A patient with a history of mood disorder and prolonged sertraline use presents with increased cortisol levels, mild hyponatremia, cognitive decline, and insomnia. Which intervention should the nurse prioritize to address the patient's immediate health concerns?

C) Implement a sleep hygiene program to improve insomnia and cognitive function.

A) Educate the patient on stress management techniques to reduce cortisol levels.

B) Collaborate with the healthcare provider to adjust the sertraline dosage to address hyponatremia.

C) Implement a sleep hygiene program to improve insomnia and cognitive function.

D) Advocate for a psychiatric referral to evaluate the need for alternative pharmacotherapy.

A patient with a mood disorder is undergoing non-pharmacological interventions for insomnia and stress management. Despite some improvements, she continues to experience fatigue and low mood. Which of the following nursing interventions is most appropriate to address her current symptoms while considering her treatment plan?

A) Encourage increased physical activity to combat fatigue and improve mood.

B) Recommend dietary supplements to boost energy levels and improve mood.

C) Suggest keeping a sleep diary to monitor patterns and identify triggers.

D) Advise decreasing fluid intake to prevent sertraline-induced hyponatremia.

A patient undergoing treatment for insomnia and stress management with non-pharmacological interventions reports moderate improvement but continues to experience fatigue and low mood. The healthcare team suspects sertraline-induced hyponatremia as a contributing factor. Which nursing action is most appropriate to address the patient's current condition?

C) Monitor the patient's sodium levels and report any abnormal results to the healthcare provider.

A) Increase the patient's fluid intake to correct potential hyponatremia.

B) Educate the patient about the potential side effects of sertraline, including hyponatremia.

C) Monitor the patient's sodium levels and report any abnormal results to the healthcare provider.

D) Suggest discontinuing sertraline immediately to prevent further hyponatremia.

A patient who has been on sertraline for depression is experiencing mild hyponatremia and elevated liver enzymes. The healthcare team decides to transition her to escitalopram and add aripiprazole. What is the most important nursing action when initiating this new medication regimen?

A) Monitor the patient's sodium levels closely.

B) Educate the patient about potential side effects of aripiprazole.

C) Assess the patient's mood and energy levels weekly.

D) Evaluate the patient's liver function tests monthly.

A patient with a history of major depressive disorder is experiencing mild hyponatremia and elevated liver enzymes. The healthcare team plans to taper sertraline and transition to escitalopram, while also introducing low-dose aripiprazole. Which nursing action is most important in managing this patient's care during the medication transition?

A) Monitor the patient's sodium levels closely to prevent worsening hyponatremia.

B) Educate the patient about potential side effects of aripiprazole, such as weight gain.

C) Assess the patient's mood and energy levels to evaluate the effectiveness of the new medication regimen.

D) Observe for signs of serotonin syndrome as the patient transitions between SSRIs.

A patient transitioning to escitalopram and aripiprazole for depression exhibits mild hyponatremia. What is the most appropriate nursing intervention to address this electrolyte imbalance?

C) Encourage dietary intake of sodium-rich foods under dietary supervision.

B) Administer sodium supplements orally to quickly elevate sodium levels.

C) Encourage dietary intake of sodium-rich foods under dietary supervision.

D) Initiate intravenous saline infusion to correct sodium levels promptly.

A patient with a history of mood disorder is being treated for mild anemia. Her hemoglobin level has decreased from 12.0 g/dL to 10.5 g/dL over two weeks. She reports occasional dizziness and mild fatigue. Which nursing intervention would be most appropriate to address her anemia while considering her psychiatric condition?

A) Encourage increased intake of foods rich in iron and vitamin C

B) Administer a high-dose iron supplement once daily without dietary changes

C) Suggest reduction of cognitive-behavioral therapy sessions to conserve energy

D) Recommend bed rest to prevent dizziness and fatigue

A patient with a history of mood disorder is being treated for mild anemia and has a current hemoglobin level of 10.5 g/dL. Which nursing intervention is most important to implement first to address the anemia while considering the patient's overall treatment plan?

A) Administer prescribed iron supplements and monitor for gastrointestinal side effects.

B) Educate the patient on increasing dietary intake of iron-rich foods such as spinach and red meat.

C) Collaborate with the dietitian to develop a meal plan that supports both hematologic and psychiatric health.

D) Assess the patient's current medications for potential interactions that may exacerbate anemia.

MOOD DISORDER - Nursing Case Study

Pathophysiology

• Primary mechanism: Neurotransmitter Imbalance - Mood disorders often involve dysregulation of key neurotransmitters such as serotonin, norepinephrine, and dopamine, which are critical for regulating mood, emotion, and cognition.

• Secondary mechanism: Neuroplasticity Alterations - Changes in brain structure and function, such as reduced neuroplasticity and altered neural circuits, particularly in areas like the prefrontal cortex and hippocampus, contribute to mood dysregulation and the persistence of mood disorders.

• Key complication: Chronic Stress and HPA Axis Dysregulation - Prolonged stress can lead to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, exacerbating mood disturbances and contributing to a cycle of worsening symptoms and reduced resilience against stress.

Patient Profile

Demographics:

32-year-old female, teacher

History:

• Key past medical history: Diagnosed with major depressive disorder 5 years ago, history of anxiety

• Current medications: Sertraline 100 mg daily, occasional use of lorazepam

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Persistent low mood and fatigue

• Key symptoms: Insomnia, lack of concentration, irritability, weight loss, increased anxiety

• Vital signs: Blood pressure 145/90 mmHg, heart rate 95 bpm, respiratory rate 20 breaths per minute, temperature 98.6°F

Section 1

As the clinical team continues to monitor the patient's condition, new diagnostic results reveal additional concerns. Laboratory tests indicate a notable increase in the patient's cortisol levels, suggesting further dysregulation of the HPA axis. This finding aligns with the patient's reported symptoms of increased anxiety and irritability, underscoring the impact of chronic stress. Additionally, a comprehensive metabolic panel reveals mild hyponatremia, potentially linked to the prolonged use of sertraline, which may be contributing to her persistent fatigue and low mood.

The patient also undergoes a thorough psychiatric evaluation to assess the current severity of her mood disorder. The evaluation highlights a significant deterioration in her cognitive function, with prominent deficits in concentration and decision-making abilities. This cognitive decline is thought to be related to ongoing neuroplasticity alterations, particularly in the prefrontal cortex. Her persistent insomnia exacerbates these cognitive issues, further impairing her ability to perform effectively in her role as a teacher and manage daily stressors.

In response to these findings, the healthcare team considers adjustments to her treatment plan. There is a need for careful clinical reasoning to balance the benefits and risks of modifying her current medication regimen, especially given her history of anxiety and the potential side effects of alternative therapies. Additionally, the team explores non-pharmacological interventions to address her insomnia and stress management, recognizing that improving her sleep quality and resilience to stress could be pivotal in mitigating the progression of her mood disorder. These considerations set the stage for the patient's next steps in her treatment journey, emphasizing a holistic approach to managing her complex clinical picture.

Section 2

As the healthcare team continues to fine-tune the patient's treatment plan, they decide to focus on addressing her insomnia and stress management through non-pharmacological interventions. The patient is introduced to cognitive-behavioral therapy for insomnia (CBT-I), which aims to identify and alter thoughts and behaviors that contribute to her sleep difficulties. Concurrently, she begins mindfulness-based stress reduction (MBSR) techniques to enhance her resilience to stress, given her elevated cortisol levels. The team anticipates that by improving her sleep quality and stress management, they can indirectly alleviate some of her mood disorder symptoms, such as anxiety and irritability.

After a few weeks of these interventions, the patient reports moderate improvement in her sleep patterns, noting that she falls asleep more quickly and experiences fewer nighttime awakenings. This positive change is reflected in her follow-up assessments, which reveal a slight reduction in cortisol levels, suggesting a degree of stabilization in her stress response. Additionally, her concentration and decision-making abilities show marginal improvement, indicating that the cognitive decline may be partially reversible with better sleep and stress management.

Despite these encouraging signs, the patient still experiences persistent fatigue and low mood, prompting the team to revisit her medication regimen. They consider the possibility of sertraline-induced hyponatremia as a contributing factor and weigh the risks and benefits of adjusting her antidepressant therapy. Given her history of anxiety, the team contemplates transitioning to an alternative SSRI with a more favorable side effect profile for electrolyte balance, or potentially augmenting her treatment with a low-dose atypical antipsychotic to target her cognitive symptoms. As they deliberate these options, the team emphasizes the importance of maintaining an open dialogue with the patient, ensuring her preferences and concerns are integral to the decision-making process. This comprehensive approach sets the stage for further refinements in her treatment plan, aiming to achieve a more balanced management of her complex mood disorder.

Section 3

As the healthcare team continues to monitor the patient's progress, new diagnostic results offer valuable insights into her ongoing symptoms. Recent laboratory tests reveal a mild hyponatremia, with her sodium levels falling to 133 mmol/L, which is slightly below the normal range. This finding raises a red flag for potential sertraline-induced hyponatremia, prompting the team to consider the implications of her current antidepressant regimen on her electrolyte balance. Additionally, a comprehensive metabolic panel highlights elevated liver enzymes, indicating possible hepatic strain, which necessitates a closer evaluation of her medication effects and overall health status.

Alongside these lab results, the patient's psychiatric evaluation suggests a persistent low mood, despite improvements in her sleep and stress management. While she reports fewer instances of anxiety and irritability, her energy levels remain notably low, affecting her daily functioning. A reassessment of her mental status examination reveals ongoing psychomotor retardation and passive suicidal ideation, though without active intent or plan. These findings compel the team to prioritize a delicate balance between managing her mood disorder symptoms and addressing the emerging complications from her treatment regimen.

In light of these developments, the team opts to taper her sertraline dose cautiously while initiating a transition to escitalopram, an SSRI with a lower risk of inducing hyponatremia. Concurrently, they introduce a low-dose atypical antipsychotic, aripiprazole, to better target her cognitive symptoms and boost her energy levels. Throughout this process, the team remains committed to engaging the patient in ongoing discussions about her treatment preferences and concerns, ensuring that any changes align with her goals for recovery. This strategic shift in her treatment plan aims to mitigate the adverse effects observed and propel her toward a more stable and balanced mood state.

Section 4

As the treatment adjustments are implemented, the healthcare team closely monitors the patient's response to the new regimen. Within a week of transitioning to escitalopram and introducing aripiprazole, the patient exhibits a subtle yet promising improvement in her energy levels, reflected in her increased engagement during therapy sessions and a slight uptick in her participation in daily activities. However, a repeat lab evaluation reveals persistent mild hyponatremia, with sodium levels now at 131 mmol/L, necessitating a continued focus on her electrolyte balance. The team decides to enhance her dietary intake of sodium under dietary supervision while maintaining vigilance over her fluid intake to prevent further dilutional hyponatremia.

Concurrently, the patient's liver function tests show a slight decrease in enzyme levels, suggesting a gradual alleviation of hepatic strain since the modification of her antidepressant regimen. Despite these positive trends, her psychiatric assessment indicates that while her mood has stabilized and psychomotor retardation is less pronounced, passive suicidal ideation persists, albeit with no active intent. This ongoing concern prompts the team to intensify her psychotherapeutic support and consider the possibility of adjunctive therapies, such as cognitive-behavioral therapy, to address underlying cognitive distortions contributing to her low mood and self-worth. The team remains committed to interdisciplinary collaboration and continuous evaluation to ensure a comprehensive approach to her complex health needs, setting the stage for further adjustments as necessary to optimize her recovery journey.

Section 5

As the healthcare team continues to monitor the patient, a new set of diagnostic results reveals additional insights into her current condition. A comprehensive metabolic panel indicates that her sodium levels have slightly improved to 133 mmol/L, suggesting that the dietary interventions are beginning to stabilize her electrolyte balance. However, a recent complete blood count shows an unexpected drop in her hemoglobin levels, now at 10.5 g/dL, down from 12.0 g/dL two weeks prior. This mild anemia prompts the team to consider potential causes, including nutritional deficiencies or medication side effects, and they decide to investigate further with additional testing, including an iron panel and vitamin B12 levels.

Clinically, the patient reports experiencing occasional dizziness and mild fatigue, which the team associates with her lower hemoglobin levels. Her blood pressure remains stable at 115/75 mmHg, and her heart rate is slightly elevated at 92 beats per minute, possibly reflecting her body's compensatory response to the anemia. Despite these challenges, her psychiatric evaluation continues to show gradual improvement. Her passive suicidal ideation remains present but is less frequent, and she expresses a willingness to engage more actively in her cognitive-behavioral therapy sessions.

The team collaborates to address these new complications, prioritizing the need to correct her anemia while maintaining her psychiatric stability. They consider introducing an iron supplement and adjusting her diet to support hematological health. This plan requires careful monitoring to ensure that it does not interfere with her ongoing treatment for mood disorder. As the team navigates these developments, they remain focused on the patient's holistic recovery, recognizing the intricate interplay between her physical and mental health as they work towards an optimal therapeutic balance.